TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Nova Biomedical initiated a global medical device correction on July 24, 2026, for the Gen 2.0 StatStrip Glucose Hospital Meter System after identifying a software issue that may associate a glucose result with the wrong patient. The company reported one U.S. adverse event involving inappropriate insulin administration and no serious adverse events related to the issue. Nova recommends identity checks after scanning and when results appear, and plans a phased software update in November.
Nova Biomedical has initiated a global medical device correction for its StatStrip Glucose Hospital Meter System after a software issue was found that may associate a glucose result with the wrong patient. The issue affects the system’s Gen 2.0 model; Nova said it received one U.S. adverse-event report involving inappropriate insulin administration based on another patient’s result, and that no serious adverse events related to the issue had been reported.
Nova said the problem can occur after a healthcare worker scans a patient ID barcode: previous patient information may remain on the meter screen. If that information is accepted and not caught, the glucose result may be assigned to the wrong patient’s medical record. A provider could then make a treatment decision based on another person’s reading. Nova warned of possible delayed or unnecessary treatment, including inappropriate insulin administration, or failure to treat the intended patient. The company said the potential severity depends on the patient’s actual glucose status and clinical condition.
According to the company announcement posted by the FDA, Nova received one U.S. adverse-event report on July 17, 2026, before the correction began. The report involved inappropriate insulin administration based on another patient’s glucose result. Nova said it had received no reports of this event outside the United States and no serious adverse events related to the issue. The announcement does not provide further details about the patient or outcome.
The correction applies to all serial numbers of the listed affected products, with distribution varying by product and market. These include the StatStrip Glucose Hospital Meter System and multipack, as well as specified StatStrip Glucose and β-Ketone Meter versions distributed in markets including Japan, Germany, the United Kingdom and Canada. Nova said the issue applies only to the newest, Gen 2.0 model and does not affect the previously released Gen 1.0, 1.75, 1.86 or 1.87 systems. Customers can check Nova’s correction notice and product details or contact its support channels for guidance.
Patient Checks Before Treatment Decisions
The correction concerns the link between a test result and a patient’s record, a step that can shape care even when the meter produces a glucose reading. A correct reading attached to the wrong person could still lead to a clinical decision being made for the wrong patient. Nova specifically identifies possible delayed treatment, unnecessary treatment and inappropriate insulin administration as potential consequences; these are described as risks, not as outcomes confirmed in every affected device.
For healthcare facilities, the immediate issue is operational: identify whether they use an affected Gen 2.0 device, follow the company’s verification steps, and decide whether an alternative device is available. Nova has placed a shipment hold on all StatStrip Glucose Hospital Meter Systems while corrective actions are developed and validated. That may affect supply while the company works on a software change, though the announcement does not quantify the hold’s effect on availability.
The company’s interim advice adds manual identity checks at more than one point in the workflow. That matters because Nova says users should not assume the patient ID shown when a barcode is scanned will necessarily be the same ID displayed with the final result. The company says its mitigation measures are intended to reduce the risk while a software update is prepared.
glucose meter patient ID barcode scanner
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Correction Scope and Company Response
Nova’s announcement is dated October 5, 2026, and the FDA published it the following day. The FDA page identifies it as a company announcement posted as a public service and says the agency does not endorse the product or company. Nova states that it initiated the global correction on July 24, 2026, after receiving the adverse-event report on July 17.
Nova said the correction is limited to the Gen 2.0 StatStrip Glucose Hospital Meter System and specified related meter versions. It states that earlier StatStrip hospital meter generations—Gen 1.0, Gen 1.75, Gen 1.86 and Gen 1.87—are not affected by this issue. The product list in the notice identifies part numbers, descriptions, device identifiers and distribution regions; facilities should use that list and Nova’s customer instructions rather than infer coverage from the StatStrip name alone.
The company says it is verifying and validating a software update and plans to introduce it in a phased rollout in November 2026. Nova says the update is intended to address known factors contributing to the correction and will also include other improvements it describes as non-safety-related. The company has not said in this notice which customers or locations will receive the update first.
““When a patient ID barcode is scanned, prior patient information may remain on the meter screen, which if accepted, will lead to glucose result being assigned to the wrong patient’s medical record.””
— Nova Biomedical
hospital glucose meter with patient verification
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Open Questions on Rollout and Impact
The announcement does not identify the affected meter serial numbers individually because Nova says the correction covers all serial numbers of the listed products. It also does not provide a total number of devices or facilities affected, or a breakdown of how many are in use in each market. The precise number of patients potentially exposed to the issue is not stated.
Nova reports one adverse event in the United States and no serious adverse events related to the issue, but the notice provides no further information about the patient’s condition or outcome. It does not establish how often the screen behavior has occurred, whether additional cases have gone unreported, or how many results may have been assigned to incorrect records. Those points remain unclear from the announcement.
The timing and sequence of the planned software update are also not fully specified. Nova says it intends a phased rollout in November, but the notice does not set out the rollout schedule, the length of the shipment hold, or whether additional corrective steps may follow. The company says it will continue monitoring performance and evaluate further improvements as appropriate.
blood glucose testing kit for hospitals
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Facilities Await November Software Update
Nova says it is working to verify and validate a software update, with a phased rollout planned for November 2026. Until that update becomes available, the company advises users to turn on patient validation and operator log software configurations where available in the StatStrip meter system and NovaNet middleware.
For each test, Nova recommends confirming that the patient name, date of birth and other identifying information on the confirmation screen match the person being tested before selecting “Accept.” It also advises checking the patient ID again on the result screen. If a result is assigned to the wrong patient, users should notify their administrator immediately. Nova says facilities with an alternative device should stop using the affected device; where no alternative is available, users should continue following the mitigation steps.
Nova directs U.S. customers to its Technical Support line at 1-800-545-6682 and Canadian customers to 1-800-263-5999; it says support is available 24 hours a day, seven days a week. Customers elsewhere should contact their authorized Nova distributor or local sales representative. The company’s correction page provides detailed instructions, and healthcare professionals and customers can report adverse events or product-quality problems through the channels described in the notice.
glucose meter with software update
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which StatStrip meters are included in the correction?
Nova says the issue affects the Gen 2.0 StatStrip Glucose Hospital Meter System and the specified related products listed in its notice, across all serial numbers of those listed products. The notice says earlier Gen 1.0, 1.75, 1.86 and 1.87 hospital meter systems are not affected by this issue. Customers should check Nova’s product list and correction instructions to confirm whether a device is included.
What should healthcare workers do before and after a test?
Nova recommends checking that the patient ID and identifying details match the person being tested after scanning the barcode and before accepting the ID. Users should check the patient ID again when the result appears, rather than assume it stayed the same. If a result is assigned to the wrong patient, the company says to notify an administrator immediately.
Was anyone harmed by the software issue?
Nova reported one U.S. adverse event involving inappropriate insulin administration based on another patient’s glucose result. The company said no serious adverse events related to the issue had been reported. Its notice does not provide further details about the patient’s condition or outcome.
When will Nova provide a software fix?
Nova says it is verifying and validating a software update and intends to begin a phased rollout in November 2026. The announcement does not specify the precise schedule or which customers will receive the update first.
Who can customers contact for help?
Nova lists U.S. Technical Support at 1-800-545-6682 and Canadian Technical Support at 1-800-263-5999, available around the clock according to the company. Customers in other countries should contact their authorized Nova Biomedical distributor or local sales representative.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
